CSL Ltd Annual Report 2021

Support for biomedical communities As we look to advance scientific knowledge and develop new solutions in areas of unmet patient needs, CSL collaborates with select partners throughout the scientific and medical communities on research and other initiatives. Among our collaborations are partnerships with medical research institutes and universities. We also offer research grants to institutes, hospitals and patient organisations. Additionally, CSL funds investigator initiated studies (IIS), projects undertaken by researchers outside CSL’s R&D activities to better understand the potential use of its products to treat new indications or therapy areas. For an IIS, CSL does not have any role in the conduct of the study and does not claim exclusivity over research outcomes, but does provide support through the provision of product and/or financial grants. In 2020/21, there were more than 20 studies supported that spanned a multitude of areas including von Willebrand disease, secondary immunodeficiency, haemophilia A and B, kidney transplant, lung transplant, chronic inflammatory demyelinating polyneuropathy and hypogammaglobulinemia. At CSL, we are committed to supporting established researchers and the researchers of tomorrow – the scientists whose discoveries will help patients lead longer, fuller lives. The CSL Centenary Fellowships are competitively selected, high-value grants available to mid-career Australians who wish to continue medical research in Australia. Two individual, five-year, A$1.25 million fellowships are awarded each year. The 2021 Centenary Fellowships were awarded to Dr Alisa Glukhova, a structural biologist at the Walter and Eliza Hall Institute of Medical Research in Melbourne, and Professor Si Ming Man of Australian National University’s John Curtin School of Medical Research. Dr Glukhova is investigating the Frizzled protein, a signal receptor in a fundamental cell communication system that guides the growth of embryos. Professor Man will use his fellowship to study disease-fighting proteins produced by the immune system and how those proteins may be used to fight infectious diseases. 11 Our Communities In 2020, four Australian medical researcher programs were awarded a CSL Research Acceleration Initiative partnership, including a A$500,000 investment in each program over two years, to fast-track the discovery of innovative biotherapies to address unmet patient needs. The CSL Research Acceleration Initiative establishes partnerships between CSL and global research organisations and includes funding as well as access to CSL R&D experts. Recipients of the 2020 funding round include researchers from the University of Western Australia, the University of Queensland and two groups fromQIMR Berghofer. Their proposals address a wide range of diseases aligned with CSL’s therapeutic areas, including immunology, cardiovascular, respiratory and transplant. Supporting promising innovation through CSL Research Acceleration Initiative CSL Limited Annual Report 2020/21 56